HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy.

Abstract
Bronchioloalveolar carcinoma is a fascinating and unusual variant of nonsmall-cell lung cancer that has a tendency towards an indolent course and to metastasize to the lung rather than distant organs. Chemotherapy has shown activity in advanced bronchioloalveolar carcinoma but response rates remain low. Epidermal growth factor receptor tyrosine kinase inhibitors have shown impressive activity against bronchioloalveolar carcinoma in trials. New data suggest that epidermal growth factor receptor mutations and gene copy number may predict subsets of patients who could most benefit from these novel agents. These new findings may point the way to a new era in which we can predict which patients will respond to epidermal growth factor receptor tyrosine kinase inhibitors and thus allow us to tailor therapy to the individual patient.
AuthorsBalvindar S Johal, Janessa Laskin
JournalExpert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 6 Issue 10 Pg. 1411-9 (Oct 2006) ISSN: 1744-8328 [Electronic] England
PMID17069526 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
Topics
  • Adenocarcinoma, Bronchiolo-Alveolar (drug therapy, epidemiology)
  • Antineoplastic Agents (administration & dosage)
  • Drug Delivery Systems (methods, trends)
  • Humans
  • Lung Neoplasms (drug therapy, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: